Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study

Liarakos, Alexandros L; Hasan, Nebras; Crabtree, Thomas S J; Leelarathna, Lalantha; Hammond, Peter; Hussain, Sufyan; Haq, Masud; Aslam, Aisha; Gatdula, Erneda; Gibb, Fraser W; Lumb, Alistair; Bull, Kirsty; Chinnasamy, Eswari; Carrieri, Giorgio; Williams, David M; Choudhary, Pratik; Ryder, Robert E J; Wilmot, Emma G

Abstract

Aims
To evaluate real-world outcomes in people with Type 1 Diabetes (PwT1D) initiated on Omnipod DASH® Insulin Management System

Methods
Anonymized clinical data were submitted to a secure web-based tool within the National Health Service network. Hemoglobin A1c (HbA1c), sensor-derived glucometrics, total daily dose of insulin (TDD), and patient-reported outcome changes between baseline and follow-up were assessed. Individuals were classified to “new-to-pump” (switched from multiple daily injections) and “established-on-pump” (switched from a tethered insulin pump) groups.

Results
276 individuals from 11 centers [66.7 % female; 92 % White British; median age 41 years (IQR 20–50); diabetes duration 20 years (IQR 11–31); 49.3 % within “new-to-pump” group] were included. Baseline HbA1c was 8.0 ± 1.3 % (64 ± 14 mmol/mol). At follow-up [3 years (IQR 1.5–3.2)], HbA1c reduced by 0.3 % [(3 mmol/mol); p = 0.002] across the total population, 0.4 % [(5 mmol/mol); p = 0.001] in those “new-to-pump” and remained unchanged in those “established-on-pump”. TDD decreased in the “new-to-pump” cohort (baseline:44.9 ± 21.0units vs follow-up:38.1 ± 15.4units, p = 0.002). Of those asked, 141/143 (98.6 %) stated Omnipod DASH had a positive impact on quality of life.

Conclusions
Omnipod DASH was associated with improvements in HbA1c in PwT1D “new-to-pump” and maintained previous HbA1c levels in those “established-on-pump”. User satisfaction in all groups and TDD reduction in those “new-to-pump” were reported.

Citation

Liarakos, A. L., Hasan, N., Crabtree, T. S. J., Leelarathna, L., Hammond, P., Hussain, S., Haq, M., Aslam, A., Gatdula, E., Gibb, F. W., Lumb, A., Bull, K., Chinnasamy, E., Carrieri, G., Williams, D. M., Choudhary, P., Ryder, R. E. J., & Wilmot, E. G. (2024). Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study. Diabetes Research and Clinical Practice, 209, Article 111597. https://doi.org/10.1016/j.diabres.2024.111597

• Journal Article Type: Article
• Acceptance Date: Feb 24, 2024
• Online Publication Date: Feb 27, 2024
• Publication Date: 2024-03
• Deposit Date: Mar 4, 2024
• Publicly Available Date: Mar 4, 2024
• Journal: Diabetes Research and Clinical Practice
• Print ISSN: 0168-8227
• Electronic ISSN: 1872-8227
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 209
• Article Number: 111597
• DOI: https://doi.org/10.1016/j.diabres.2024.111597
• Keywords: Continuous subcutaneous insulin infusion; Omnipod DASH; Tubeless insulin pump; Type 1 diabetes mellitus; Diabetes technology
• Public URL: https://nottingham-repository.worktribe.com/output/32162174
• Publisher URL: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00081-0/fulltext